Clinical trial
A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).
NCT06168383 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 5, 2024
- Completion date
- January 16, 2026
- Enrollment
- 186 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-alcoholic steatohepatitis (nash)